|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01877 JUNSHI BIO
Nominal 
12.020 +0.040 (+0.334%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 1,502,550 | 3.375% | 1,453,493 | 4,024,841 | 1,594,897 | 775,089 |
| Cost of Sales | (667,290) | 26.793% | (526,282) | (1,258,187) | (372,531) | (90,684) |
| Gross Profit | 835,260 | -9.917% | 927,211 | 2,766,654 | 1,222,366 | 684,405 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (23,484) | 49865.957% | (47) | 342 | (255) | 1,038 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (60,484) | -14.850% | (71,032) | (48,463) | (3,805) | (2,527) | |
| Profit / (Loss) before Taxation | (2,489,887) | -6.927% | (2,675,202) | (592,648) | (1,669,461) | (763,124) | |
| Taxation | (43,995) | -- | 93,107 | (135,533) | 3,822 | 18,891 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 252,258 | 28.685% | 196,028 | 9,624 | 0 | 311 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (2,281,624) | -4.377% | (2,386,067) | (718,557) | (1,665,639) | (743,922) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (70,420) | 122.510% | (31,648) | (9,146) | 9,113 | (15,922) |
| Depreciation & Amortisation | 303,220 | 14.897% | 263,907 | 262,559 | 151,362 | 59,591 |
| Directors' Emoluments | 55,345 | -19.429% | 68,691 | 102,780 | 96,137 | 34,312 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -232.000 | -10.769% | -260.000 | -80.000 | -202.000 | -95.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (2.045) | -- | (1.935) | (0.719) | (1.817) | (1.515) |
| NBV per share ($) | 7.275 | -- | 9.667 | 8.741 | 6.695 | 3.811 |
| Remarks: | Real time quote last updated: 24/12/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -645,691,000 |
| %Change | -35.199% |
| EPS / (LPS) | RMB -0.660 |
| NBV Per Share (¥) | RMB 6.591 |